|
NOP58 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62481139653892E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
<1E-12 |
| Normal-vs-Stage2 |
1.86628490439489E-13 |
| Normal-vs-Stage3 |
1.11022302462516E-14 |
| Normal-vs-Stage4 |
1.68132174849234E-12 |
| Stage1-vs-Stage2 |
4.021300E-03 |
| Stage1-vs-Stage3 |
9.811800E-02 |
| Stage1-vs-Stage4 |
6.522100E-02 |
| Stage2-vs-Stage3 |
1.808830E-01 |
| Stage2-vs-Stage4 |
3.542400E-01 |
| Stage3-vs-Stage4 |
6.340800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
2.88660000347107E-08 |
| Normal-vs-Asian |
7.66700003484999E-09 |
| Caucasian-vs-AfricanAmerican |
6.967000E-01 |
| Caucasian-vs-Asian |
3.263000E-01 |
| AfricanAmerican-vs-Asian |
3.099600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.11022302462516E-16 |
| Normal-vs-Female |
1.62447832963153E-12 |
| Male-vs-Female |
2.871600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62481139653892E-12 |
| Normal-vs-Age(41-60Yrs) |
<1E-12 |
| Normal-vs-Age(61-80Yrs) |
1.62581059726108E-12 |
| Normal-vs-Age(81-100Yrs) |
4.12080003453497E-09 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.192000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
9.879200E-03 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.885800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.464820E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.345200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
2.054200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.131000E-01 |
| Classical-VS-Follicular |
2.398500E-04 |
| Classical-VS-Other |
3.681000E-01 |
| Classical-VS-Normal |
4.52580195542396E-11 |
| Tall-VS-Follicular |
1.215160E-01 |
| Tall-VS-Other |
7.382600E-01 |
| Tall-VS-Normal |
1.19560000011454E-07 |
| Follicular-VS-Other |
6.120000E-01 |
| Follicular-VS-Normal |
1.62658775337832E-12 |
| Other-VS-Normal |
8.022700E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.11022302462516E-16 |
| Normal-vs-N1 |
3.16209947115453E-10 |
| N0-vs-N1 |
1.211160E-01 |
|
|
